Home›Trial›NCT05683379
NCT05683379RECRUITING

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

Study Summary

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).

Conditions
Duchenne Muscular Dystrophy
Interventions / Drugs
AAV8 DetectCDx
View on ClinicalTrials.gov ↗
Sponsor
RGNX
REGENXBIO Inc
Gene Therapy
D42/100
Study Details
Enrollment200 participants
Primary Completion—
Lead SponsorREGENXBIO Inc.
Data Retrieved2026-04-11 04:25:55.708121+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 200 participants
Sponsor Catalyst Profile

REGENXBIO Inc (RGNX) is the sponsoring company for this trial. BiotechSign currently grades this company D (42/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

RGNX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.